OBI Pharma Inc., of Taipei, Taiwan, reported preclinical results from a study of OBI-3424 in a patient-derived xenograft model of T-cell acute lymphoblastic leukemia. OBI-3424, which targets aldo-keto reductase 1c3 and releases a DNA alkylating agent, produced objective responses in eight of nine mice with a significant reduction in bone marrow infiltration at day 28 in four of six evaluable mice.